Autolus Therapeutics (AUTL) Sets New 1-Year High at $40.98

Autolus Therapeutics Ltd – (NASDAQ:AUTL) reached a new 52-week high on Thursday . The stock traded as high as $40.98 and last traded at $38.89, with a volume of 50475 shares. The stock had previously closed at $31.20.

AUTL has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage on shares of Autolus Therapeutics in a report on Tuesday, July 17th. They issued a “buy” rating and a $37.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Autolus Therapeutics in a research report on Friday, November 2nd. William Blair assumed coverage on shares of Autolus Therapeutics in a research report on Tuesday, July 17th. They issued an “outperform” rating on the stock. Goldman Sachs Group assumed coverage on shares of Autolus Therapeutics in a research report on Thursday, July 26th. They issued a “neutral” rating on the stock. Finally, Wells Fargo & Co assumed coverage on shares of Autolus Therapeutics in a research report on Tuesday, July 17th. They issued an “outperform” rating and a $38.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $40.00.

Institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC bought a new stake in Autolus Therapeutics in the second quarter worth about $498,000. Jennison Associates LLC bought a new stake in Autolus Therapeutics in the second quarter worth about $3,168,000. Hermes Investment Management Ltd. bought a new stake in Autolus Therapeutics in the second quarter worth about $1,248,000. Essex Investment Management Co. LLC raised its holdings in Autolus Therapeutics by 112.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 80,138 shares of the company’s stock worth $2,458,000 after buying an additional 42,396 shares during the period. Finally, Aquilo Capital Management LLC acquired a new stake in Autolus Therapeutics during the 2nd quarter worth about $4,018,000. Hedge funds and other institutional investors own 21.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Autolus Therapeutics (AUTL) Sets New 1-Year High at $40.98” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/11/10/autolus-therapeutics-autl-sets-new-1-year-high-at-40-98.html.

Autolus Therapeutics Company Profile (NASDAQ:AUTL)

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Read More: Insider Trading

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply